BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang W, Hu B, Qin JJ, Cheng JW, Li X, Rajaei M, Fan J, Yang XR, Zhang R. A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance. Genes Dis 2019;6:419-30. [PMID: 31832522 DOI: 10.1016/j.gendis.2019.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu L, Xu Z, Yu B, Tao L, Cao Y. Berbamine Inhibits Cell Proliferation and Migration and Induces Cell Death of Lung Cancer Cells via Regulating c-Maf, PI3K/Akt, and MDM2-P53 Pathways. Evid Based Complement Alternat Med 2021;2021:5517143. [PMID: 34306137 DOI: 10.1155/2021/5517143] [Reference Citation Analysis]
2 Fhu CW, Ali A. Dysregulation of the Ubiquitin Proteasome System in Human Malignancies: A Window for Therapeutic Intervention. Cancers (Basel) 2021;13:1513. [PMID: 33805973 DOI: 10.3390/cancers13071513] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
3 Zhou Z, Zalutsky MR, Chitneni SK. Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation. Mol Pharm 2021;18:3871-81. [PMID: 34523337 DOI: 10.1021/acs.molpharmaceut.1c00531] [Reference Citation Analysis]
4 Ng CX, Le CF, Tor YS, Lee SH. Hybrid Anticancer Peptides DN1 and DN4 Exert Selective Cytotoxicity Against Hepatocellular Carcinoma Cells by Inducing Both Intrinsic and Extrinsic Apoptotic Pathways. Int J Pept Res Ther 2021;27:2757-75. [DOI: 10.1007/s10989-021-10288-8] [Reference Citation Analysis]
5 Yu D, Xu Z, Cheng X, Qin J. The role of miRNAs in MDMX-p53 interplay. J Evid Based Med 2021;14:152-60. [PMID: 33988919 DOI: 10.1111/jebm.12428] [Reference Citation Analysis]
6 Wang W, Wang X, Rajaei M, Youn JY, Zafar A, Deokar H, Buolamwini JK, Yang J, Foster JH, Zhou J, Zhang R. Targeting MDM2 for Neuroblastoma Therapy: In Vitro and In Vivo Anticancer Activity and Mechanism of Action. Cancers (Basel) 2020;12:E3651. [PMID: 33291373 DOI: 10.3390/cancers12123651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Martinho MS, Nancarrow DJ, Lawrence TS, Beer DG, Ray D. Chaperones and Ubiquitin Ligases Balance Mutant p53 Protein Stability in Esophageal and Other Digestive Cancers. Cell Mol Gastroenterol Hepatol 2021;11:449-64. [PMID: 33130332 DOI: 10.1016/j.jcmgh.2020.10.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Zhang S, Wang Y, Sun Y, Zhao G, Wang J, Liu L, Liu F, Wang P, Xu X. 4′,7-Di-O-methylnaringenin (DMNG), a naringenin derivative, activates p53 signal pathway through down-regulating MDM2. Journal of Functional Foods 2022;89:104962. [DOI: 10.1016/j.jff.2022.104962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wu MY, Tang YP, Liu JJ, Liang R, Luo XL. Global transcriptomic study of circRNAs expression profile in sorafenib resistant hepatocellular carcinoma cells. J Cancer 2020;11:2993-3001. [PMID: 32226514 DOI: 10.7150/jca.39854] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
10 He K, Liu S, Xia Y, Xu J, Liu F, Xiao J, Li Y, Ding Q, Lu L, Xiang G, Zhan M. CXCL12 and IL7R as Novel Therapeutic Targets for Liver Hepatocellular Carcinoma Are Correlated With Somatic Mutations and the Tumor Immunological Microenvironment. Front Oncol 2020;10:574853. [PMID: 33344233 DOI: 10.3389/fonc.2020.574853] [Reference Citation Analysis]
11 Louveau B, Jouenne F, Têtu P, Sadoux A, Gruber A, Lopes E, Delyon J, Serror K, Marco O, Da Meda L, Ndiaye A, Lermine A, Dumaz N, Battistella M, Baroudjian B, Lebbe C, Mourah S. A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping. Target Oncol 2020;15:759-71. [PMID: 33151472 DOI: 10.1007/s11523-020-00764-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Chitneni SK, Zhou Z, Watts BE, Zalutsky MR. Feasibility of Developing Radiotracers for MDM2: Synthesis and Preliminary Evaluation of an 18F-Labeled Analogue of the MDM2 Inhibitor SP-141. Pharmaceuticals (Basel) 2021;14:358. [PMID: 33924734 DOI: 10.3390/ph14040358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Chamberlain V, Drew Y, Lunec J. Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53WT Uterine Leiomyosarcoma. Cancers (Basel) 2021;14:14. [PMID: 35008180 DOI: 10.3390/cancers14010014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zhu Y, Zhang Q, Yan X, Liu L, Zhai C, Wang Q, Chai L, Li M. Ubiquitin-specific protease 7 mediates platelet-derived growth factor-induced pulmonary arterial smooth muscle cells proliferation. Pulm Circ 2021;11:20458940211046131. [PMID: 34552711 DOI: 10.1177/20458940211046131] [Reference Citation Analysis]
15 Punganuru SR, Artula V, Zhao W, Rajaei M, Deokar H, Zhang R, Buolamwini JK, Srivenugopal KS, Wang W. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action. Cells 2020;9:E1592. [PMID: 32630235 DOI: 10.3390/cells9071592] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
16 Zhang R. Meet Our Editorial Board Member. ACAMC 2021;21:937-937. [DOI: 10.2174/187152062108210128101743] [Reference Citation Analysis]